GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » Total Equity

Shanghai Haohai Biological Technology Co (HKSE:06826) Total Equity : HK$6,651 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Total Equity?

Shanghai Haohai Biological Technology Co's total equity for the quarter that ended in Mar. 2024 was HK$6,651 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Shanghai Haohai Biological Technology Co Total Equity Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Total Equity Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,290.77 6,797.56 7,420.62 6,591.28 6,581.59

Shanghai Haohai Biological Technology Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6,661.75 6,520.29 6,581.59 6,650.59

Shanghai Haohai Biological Technology Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Shanghai Haohai Biological Technology Co's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=7771.843-1190.255
=6,582

Shanghai Haohai Biological Technology Co's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=7813.715-1163.126
=6,651

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co Total Equity Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » Total Equity
Comparable Companies
HKSE:02162 HKSE:01530 HKSE:06990 HKSE:09969 HKSE:06660 HKSE:01541 HKSE:09966 HKSE:01952 HKSE:02105 HKSE:02315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
688366:China
Address
No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Website
https://www.3healthcare.com
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.
Executives
Morgan Stanley 2201 Interest of corporation controlled by you
Dalton Investments Llc 2102 Investment manager
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Templeton Investment Counsel, Llc 2102 Investment manager
Kabouter Management Llc 2102 Investment manager
Royal Bank Of Canada 2201 Interest of corporation controlled by you
Kabouter International Insight Fund, Llc 2102 Investment manager
Prudence Investment Management (hong Kong) Limited 2102 Investment manager

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines